Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.

Hdl Handle:
http://hdl.handle.net/10147/207331
Title:
Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.
Affiliation:
Centre for Systems Medicine and Department of Physiology and Medical Physics,, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Surgery,, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.
Citation:
Int J Cancer. 2011 Sep 29. doi: 10.1002/ijc.26468.
Journal:
International journal of cancer. Journal international du cancer
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207331
DOI:
10.1002/ijc.26468
PubMed ID:
21960357
Abstract:
Colorectal cancer is a leading cause of cancer-related deaths worldwide. Early diagnosis and treatment of colorectal cancer is the key to improving survival rates and as such a need exists to identify patients who may benefit from adjuvant chemotherapy. The dysregulation of the ubiquitin-proteasome system (UPS) has been implicated in oncogenesis and cancer cell survival, and proteasome inhibitors are in clinical use for a number of malignancies including multiple myeloma. In our study, we examined the protein expression of several key components of the UPS in colorectal cancer using immunohistochemistry to determine expression levels of ubiquitinylated proteins and the proteasomal subunits, 20S core and Rpt4 in a cohort of 228 patients with colon cancer. Multivariate Cox analysis revealed that neither the intensity of either ubiquitinylated proteins or the 20S core was predictive in either Stage II or III colon cancer for disease free survival or overall survival. In contrast, in Stage II patients increased Rpt4 staining was significantly associated with disease free survival (Cox proportional hazard ratio 0.605; p = 0.0217). Our data suggest that Rpt4 is an independent prognostic variable for Stage II colorectal cancer and may aid in the decision of which patients undergo adjuvant chemotherapy.
Language:
ENG
ISSN:
1097-0215 (Electronic); 0020-7136 (Linking)

Full metadata record

DC FieldValue Language
dc.date.accessioned2012-02-01T10:05:01Z-
dc.date.available2012-02-01T10:05:01Z-
dc.date.issued2012-02-01T10:05:01Z-
dc.identifier.citationInt J Cancer. 2011 Sep 29. doi: 10.1002/ijc.26468.en_GB
dc.identifier.issn1097-0215 (Electronic)en_GB
dc.identifier.issn0020-7136 (Linking)en_GB
dc.identifier.pmid21960357en_GB
dc.identifier.doi10.1002/ijc.26468en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207331-
dc.description.abstractColorectal cancer is a leading cause of cancer-related deaths worldwide. Early diagnosis and treatment of colorectal cancer is the key to improving survival rates and as such a need exists to identify patients who may benefit from adjuvant chemotherapy. The dysregulation of the ubiquitin-proteasome system (UPS) has been implicated in oncogenesis and cancer cell survival, and proteasome inhibitors are in clinical use for a number of malignancies including multiple myeloma. In our study, we examined the protein expression of several key components of the UPS in colorectal cancer using immunohistochemistry to determine expression levels of ubiquitinylated proteins and the proteasomal subunits, 20S core and Rpt4 in a cohort of 228 patients with colon cancer. Multivariate Cox analysis revealed that neither the intensity of either ubiquitinylated proteins or the 20S core was predictive in either Stage II or III colon cancer for disease free survival or overall survival. In contrast, in Stage II patients increased Rpt4 staining was significantly associated with disease free survival (Cox proportional hazard ratio 0.605; p = 0.0217). Our data suggest that Rpt4 is an independent prognostic variable for Stage II colorectal cancer and may aid in the decision of which patients undergo adjuvant chemotherapy.en_GB
dc.language.isoENGen_GB
dc.titleAnalyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer.en_GB
dc.contributor.departmentCentre for Systems Medicine and Department of Physiology and Medical Physics,, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Surgery,, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.en_GB
dc.identifier.journalInternational journal of cancer. Journal international du canceren_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.